Technology evaluation: HYB-2055, Hybridon.
Hybridon is developing immunomodulatory oligonucleotides. including injectable HYB-2055 (IMOxine) which acts as an agonist of toll-like receptor 9, for the potential treatment of cancer. HYB-2055 is currently undergoing phase II clinical trials. The immunomodulatory oligonucleotides are also being investigated for the potential treatment of infectious diseases and immune disorders.